News & Events

Innovative Research Brings Potential New Class of Drugs for Patients with ALK-EML4 Fusion

Harnessing the Immune System to Tackle RET-positive Lung Cancer

Get the Answers You Need

Caregiver Starter Kit: 5 Resources

Highlights of the 2022 AACR meeting

Upcoming Events

General Virtual Meetup

Tue, 2/14/2023 - 12:00 PM ET

For patients/survivors - Join us every Tuesday for this general… more

Thursday Happy Hour Virtual Meetup

Thu, 2/16/2023 - 6:30 PM ET

For patients/survivors General meetup for those impacted by lung… more

General Virtual Meetup

Tue, 2/21/2023 - 12:00 PM ET

For patients/survivors - Join us every Tuesday for this general… more

Thursday Caregiver Connection

Thu, 2/23/2023 - 8:00 PM ET

For caregivers, family & friends - You don’t need to take on… more

General Virtual Meetup

Tue, 2/28/2023 - 12:00 PM ET

For patients/survivors - Join us every Tuesday for this general… more

Medicaid Patients With NSCLC May Be Undertreated With Life-prolonging Targeted Therapies

Medicaid Patients With NSCLC May Be Undertreated With Life-prolonging Targeted Therapies

Takeda's Exkivity to compete against Janssen's Rybrevant in rare NSCLC treatment market

Takeda's Exkivity to compete against Janssen's Rybrevant in rare NSCLC treatment market

Guideline for oncogene-addicted metastatic NSCLC issued by ESMO

Guideline for oncogene-addicted metastatic NSCLC issued by ESMO

FDA Approves FoundationOne Liquid CDx to Identify Genomic Profile in NSCLC

FDA Approves FoundationOne Liquid CDx to Identify Genomic Profile in NSCLC

Differences in Tumor Biology Could Partly Explain Disparities in Metastatic NSCLC

Differences in Tumor Biology Could Partly Explain Disparities in Metastatic NSCLC

Ellipses begins patient dosing in EP0031, a next generation selective RET inhibitor

Ellipses begins patient dosing in EP0031, a next generation selective RET inhibitor

Blueprint Medicines: A Slow But Steady Blueprint For Success

Blueprint Medicines: A Slow But Steady Blueprint For Success

Updates Results Support Repotrectinib in ROS1+ NSCLC

Updates Results Support Repotrectinib in ROS1+ NSCLC

Targeted Therapy, Immunotherapy Propel 10 Years of Progress in NSCLC

Targeted Therapy, Immunotherapy Propel 10 Years of Progress in NSCLC